Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

Healthcare Remains Steady As Market Approaches A Key Level • Prudent Biotech

Healthcare Remains Steady As Market Approaches A Key Level The market is approaching a key technical level. Healthcare has relatively outperformed the market and has

August 15, 2022

Social Media Physician Endorsements Raise Prickly Ethical Questions

In 2022, 28 U.S. physicians endorsing drugs or devices on X (previously Twitter) made nearly $1.5 million from companies who make these products, a cross-sectional

May 31, 2024

Sly CAR-T strategy evades ‘fratricide’ problem to aim at all blood cancers

The problem with the plan was fratricide, among other wanton cellular murders. Saar Gill and Carl June, cell therapy researchers at the University of Pennsylvania,

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.